Fujifilm Systems Integration Selects caresyntax for OR Integration

Today FUJIFILM Medical Systems announced that the company has selected caresyntax, a pioneering developer in surgical automation, analytics software, as the supplier of Fujifilm Systems Integration using caresyntax’s proprietary operating room (OR) integration and workflow automation intelligence.

As the healthcare industry continues to respond to today’s uncertainties, Fujifilm trusts this new partnership to aid hospital operations, improve workflow efficiencies of the interventional space, and meet patient demand surges as deferred procedures are rescheduled.

“As the only vendor that offers endoscopic imaging as well as modality solutions and enterprise-wide IT products—launching the Fujifilm Systems Integration business will allow Fujifilm to capture the full clinical value chain,” says Devon Bream, MPH, FACHE, Global Vice President Endoscopy, General Manager Systems Integration, FUJIFILM Medical Systems U.S.A., Inc. “We selected caresyntax as our supplier because the team has a demonstrated history in developing data-driven integration that provides the total visibility to achieve increased workflow efficiency, patient safety, and surgical performance.”

Together Fujifilm and caresyntax will develop a systems integration solution designed specifically for image and data integration in the operating room (OR/Hybrid OR) and endoscopy suite that will connect Fujifilm’s medical image capture products and Synapse brand viewing, storage, and analytics technologies.

“Fujifilm’s vision of closing the loop between its powerful clinical informatics ecosystem and its trusted offerings at the point of care will be a resounding success that will create value for caregivers and patients,” says Dennis Kogan, Co-Founder and CEO, caresyntax. “caresyntax is excited to leverage our robust surgical automation and analytics platform to support Fujifilm in this endeavor. We strongly believe that data-driven collaborations with health systems, medical device companies, and insurers are key to managing surgical risk and promoting smarter, safer surgery; and are proud to partner with Fujifilm in pursuit of this common goal.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version